Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) EBIT Margin: 2010-2025

Historic EBIT Margin for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Sep 2025 value amounting to 61.84%.

  • Ironwood Pharmaceuticals' EBIT Margin rose 3385.00% to 61.84% in Q3 2025 from the same period last year, while for Sep 2025 it was 36.34%, marking a year-over-year increase of 1012.00%. This contributed to the annual value of 26.50% for FY2024, which is 24004.00% up from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported EBIT Margin of 61.84% as of Q3 2025, which was up 16.31% from 53.17% recorded in Q2 2025.
  • Ironwood Pharmaceuticals' EBIT Margin's 5-year high stood at 63.77% during Q4 2022, with a 5-year trough of -1,008.68% in Q2 2023.
  • In the last 3 years, Ironwood Pharmaceuticals' EBIT Margin had a median value of 31.98% in 2023 and averaged -66.87%.
  • Per our database at Business Quant, Ironwood Pharmaceuticals' EBIT Margin slumped by 106,592bps in 2023 and then surged by 103,514bps in 2024.
  • Over the past 5 years, Ironwood Pharmaceuticals' EBIT Margin (Quarterly) stood at 48.32% in 2021, then surged by 1,546bps to 63.77% in 2022, then tumbled by 3,180bps to 31.98% in 2023, then surged by 280bps to 34.78% in 2024, then skyrocketed by 3,385bps to 61.84% in 2025.
  • Its EBIT Margin was 61.84% in Q3 2025, compared to 53.17% in Q2 2025 and -70.75% in Q1 2025.